Market Overview

Bristol-Myers Squibb Says Orencia Approved by EU

Related BMY
Berenberg Initiates Bristol-Myers Squibb With Hold
Benzinga's Top Initiations
Merck got EU's CHMP (Investor's Business Daily)

Bristol-Myers Squibb announced today that the European Commission has granted marketing authorisation for the subcutaneous formulation of ORENCIA ® (abatacept), in combination with methotrexate (MTX), for the treatment of adults with moderate to severe active rheumatoid arthritis (RA).

Posted-In: News FDA


Related Articles (BMY)

Around the Web, We're Loving...